Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05042258 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 2025 to Jun 2027
    • Study completion date: Dec 2025 to Jun 2027
    v13
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 2024 to Aug 12, 2024
    • Site details revised
    v12
  3. Start date: Jun 2024 to Aug 2024v11
  4. Start date: Apr 2024 to Jun 2024v10
  5. Start date: Feb 2024 to Apr 2024v9
Show 7 earlier versionsHide 7 earlier versions
  1. Start date: Dec 2023 to Feb 2024
    • Primary completion date: Dec 2024 to Jun 2025
    v8
  2. Start date: Aug 2023 to Dec 2023v7
  3. Start date: May 2023 to Aug 2023
    • Primary completion date: Oct 2024 to Dec 2024
    • Study completion date: Oct 2025 to Dec 2025
    v6
  4. Start date: Feb 2023 to May 2023
    • Primary completion date: Aug 2024 to Oct 2024
    • Study completion date: Aug 2025 to Oct 2025
    v5
  5. Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago to Northwestern Universityv4 Show 5 more changesShow less
    • Start date: Nov 2022 to Feb 2023
    • Trial status: Recruiting to Not Yet Recruiting
    • Study sites: 2 to 1
    • Secondary endpoints shortened, about 136 words
    • Collaborator revised
  6. Start date: Nov 2021 to Nov 2022v3
  7. Start date: Sep 2021 to Nov 2021
    • Primary completion date: Jul 2024 to Aug 2024
    • Study completion date: Jul 2025 to Aug 2025
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old
Trial Details
NCT Number NCT05042258
Lead Sponsor Northwestern University
Collaborators: Regeneron Pharmaceuticals
Conditions
(from sponsor)		 Atopic Dermatitis, Sleep Disturbance
Related terms Dermatitis, Atopic, Parasomnias
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov